Loading
A phase 2 trial in pancreatic cancer, run by National Cancer Center, Japan, now recruiting.
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) is a phase 2, interventional study registered as NCT06159478 by National Cancer Center, Japan, with a registry enrolment figure of 32 participants, started 2023-03-29 and due to reach its primary completion in 2027-02-28. Interventions recorded: Binimetinib 15 MG. Conditions listed: Low-grade Glioma; Pancreatic Cancer. Primary outcome: Overall response rate (centrally assessed). Pancreatic eligibility wording from the registry: "Cohort B 19) Histopathologically diagnosed as pancreatic cancer (histologically not specified)". Sites: Japan. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.